It's a good idea to go against the current market sentiment on this one. Vertex Pharmaceuticals continues to generate most of its revenue from its cystic fibrosis (CF) franchise. The company's ...
Robots may not be taking the place of researchers in lab coats running clinical trials anytime soon, but AI is playing an increasingly important role in drug discovery efforts. That’s the message ...
During Vertex’s third-quarter presentation, Chief Commercial Officer Duncan McKechnie cited several numbers that suggest the launch of its long-awaited, non-opioid pain reliever Journavx is trending ...
After the FDA's landmark approval of the opioid-free acute pain reliever Journavx in January, Vertex Pharmaceuticals has hit a snag on its path to expand the potential blockbuster’s reach into ...
Vertex Pharmaceuticals (NASDAQ:VRTX) shares fell in premarket trading on Tuesday after the company's VX-993 failed to meet the primary endpoint in the Phase 2 pain study, offsetting a strong quarterly ...
Aug 4 (Reuters) - Vertex Pharmaceuticals will stop developing its experimental non-opioid painkiller as a solo treatment after a mid-stage trial failure and will not start a study for expanded use of ...
This repository contains the source code of an evolutionary algorithm designed to search for regular K_3-irregular graphs. The project combines graph theory, evolutionary computation, and practical ...
TikTok millionaires and AI tools make college look like an overpriced relic, so it’s fair to ask: are degrees even worth it anymore? The answer? Some absolutely are—and some absolutely are not. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback